No Carolina / New York / Florida        Ph: 561.316.3330

Published VITAL Study on Bactiguard’s Endotracheal Tube

What To Know

  • The VITAL study was presented for the first at the European Society of Intensive Care congress (ESICM) 2021, where it was selected as one of the top 6 best abstracts.
  • The study was a randomized-controlled double-blinded study including 323 patients, either intubated with a Bactiguard endotracheal tube or a conventional tube (both with subglottic suctioning port).

The VITAL study, by Professor Pierre Damas and his team, is now published in the well renowned journal Annals of Intensive Care. The study shows a 53% reduction of ventilator-associated pneumonia with Bactiguard’s endotracheal tube. It was presented for the first time at the European Society of Intensive Care congress (ESICM) in October 2021.

“These are very important data for critically ill patients in need of mechanical ventilation. Ventilator-associated pneumonia (VAP) is an unwanted complication associated with increased hospital length-of-stay, increased costs and increased mortality. The study data indicates that by using a Bactiguard endotracheal tube the risk of this complication is significantly reduced”, says Professor Pierre Damas.

“We are very happy for this publication of the first well-designed study with clinical relevant endpoints on the Bactiguard endotracheal tube. The previous extensive evidence on the Bactiguard technology has been broadened, and to date we have seen meaningful clinical results regardless of application area”, says Stefan Grass, Chief Medical Officer and Deputy CEO.

The study was a randomized-controlled double-blinded study including 323 patients, either intubated with a Bactiguard endotracheal tube or a conventional tube (both with subglottic suctioning port). The number of VAP cases were 22.4 per 1000 ventilator days in the control group compared with 10.5 in the Bactiguard group which was just short of significance (p=0.07). The time to occurrence of VAP was significantly reduced in the Bactiguard group (p=0.02).

The VITAL study was presented for the first at the European Society of Intensive Care congress (ESICM) 2021, where it was selected as one of the top 6 best abstracts.

Latest

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study

0
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

0
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

0
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

0
The research, presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting, included a registrational Phase 3 trial and an integrated safety analysis of six clinical studies, as well as a real-world analysis of current treatment options and gaps in the clinical management of patients with newly-diagnosed LDH.

Reports breaking medical device and biotechnololgy news

About
Press Releases
Advertise
Privacy
Cookie Policy

Contact:  561.316.3330

Offices: No. Carolina / New York

© Medical Device News Magazine 2024

By using this website you agree to accept Medical Device News Magazine Privacy Policy